eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference
16 sept. 2021 08h00 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Debuts as Publicly Traded Next-Generation Oncology Company Advancing Mature Pipeline with New Class of Cancer Therapies
25 août 2021 19h18 HE
|
eFFECTOR Therapeutics, Inc.
SAN DIEGO, Aug. 25, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Initiates Phase 2a Expansion Cohorts Evaluating Zotatifin in Breast Cancer and KRAS-mutant Non-small Cell Lung Cancer
04 août 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (eFFECTOR), a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer,...
eFFECTOR Therapeutics Doses First Patient with COVID-19 in Phase 1b Clinical Trial Evaluating Zotatifin as a Host-Targeted Antiviral Agent
22 juil. 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, July 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Therapeutics Announces Publication of Tomivosertib Preclinical Data in Cell Reports
16 juil. 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (“STRIs”) for the treatment of cancer, announced...
eFFECTOR Therapeutics to Present at JMP Securities 2021 Life Sciences Conference
14 juin 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, June 14, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (“eFFECTOR”), a biopharmaceutical company focused on pioneering the development of selective translation regulation...
eFFECTOR Therapeutics Doses First Patient in Phase 2b KICKSTART Clinical Trial
09 juin 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, June 09, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Therapeutics and Locust Walk Acquisition Corp. Announce Merger Agreement to Create Publicly Listed, Next-Generation Oncology Company Developing New Class of Cancer Therapies
27 mai 2021 08h00 HE
|
eFFECTOR Therapeutics
Gross proceeds expected to include $60 million from a committed PIPE and up to $175 million held in trust Anticipated cash resources will fund eFFECTOR’s pipeline advancement through multiple clinical...
eFFECTOR and Quantitative Biosciences Institute (QBI) at UCSF Receive $5.0 Million from DARPA to Evaluate Zotatifin in COVID-19
04 mai 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, May 04, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today...
eFFECTOR Appoints Mike Byrnes as Chief Financial Officer
07 janv. 2021 08h00 HE
|
eFFECTOR Therapeutics
SAN DIEGO, Jan. 07, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc., a leader in the development of selective translation regulation inhibitors (STRIs) for the treatment of cancer, today...